for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Pharmanutra SpA

PHNU.MI

Latest Trade

20.60EUR

Change

0.30(+1.48%)

Volume

3,343

Today's Range

20.30

 - 

20.60

52 Week Range

14.40

 - 

21.60

As of on the Italian SE (Mercato Continuo Italia) ∙ Minimum 15 minute delay

Pricing

Previous Close
20.30
Open
20.40
Volume
3,343
3M AVG Volume
0.11
Today's High
20.60
Today's Low
20.30
52 Week High
21.60
52 Week Low
14.40
Shares Out (MIL)
9.68
Market Cap (MIL)
196.52
Forward P/E
23.07
Dividend (Yield %)
2.46

Next Event

Pharmanutra SpA Annual Shareholders Meeting

Latest Developments

More

Pharmanutra H1 Net Profit Up 12% Yr/Yr

Pharmanutra Signs Deal With Wert Philippines For Distribution Of Sideral Line

Pharmanutra Signs Deal For Distribution Of Sideral In Taiwan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Pharmanutra SpA

Pharmanutra SpA is an Italy-based company engaged in the healthcare industry. The Company develops nutraceutical products and medical devices. It focuses on studying and producing formulations that are backed up in scientific research. It is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The Company offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.

Industry

Biotechnology & Drugs

Contact Info

Via delle Lenze n. 216/B

http://www.pharmanutra.it/it/

Key Stats

2.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, EUR)

2017

0.0K

2018

0.0K

2019(E)

0.1K
EPS (EUR)

2017

0.620

2019(E)

0.880
Price To Earnings (TTM)
21.90
Price To Sales (TTM)
3.96
Price To Book (MRQ)
8.34
Price To Cash Flow (TTM)
20.09
Total Debt To Equity (MRQ)
21.54
LT Debt To Equity (MRQ)
8.74
Return on Investment (TTM)
34.43
Return on Equity (TTM)
23.14

Latest News

BRIEF-Pharmanutra H1 Net Profit Up 12% Yr/Yr

Pharmanutra SpA: * H1 REVENUE EUR 25.1 MLN, UP 14% YEAR ON YEAR * H1 NET PROFIT EUR 4.0 MLN, UP 12% YEAR ON YEAR Source text for Eikon: Further company coverage: (Gdynia Newsroom)

BRIEF-Pharmanutra Top Three Shareholders Increase Their Stakes

* SAID ON TUESDAY THAT ANDREA LACORTE, ROBERTO LACORTE AND BEDA HAVE FINALIZED ACQUISITION OF 4.54 PCT STAKE IN CO PREVIOUSLY OWNED BY GIANNI LAZZARINI

BRIEF-PharmaNutra Signs Distribution Deals For Its Cetilar and Ultramag Products

* SAID ON MONDAY THAT IT SIGNED DISTRIBUTION DEALS WITH RENAPHARMA AND FRESENIUS KABI AUSTRIA

BRIEF-PharmaNutra Signs Distribution Deal For Its Cetilar Products Line In Thailand

* SAID ON DEC 18 THAT SIGNED AGREEMENT FOR DISTRIBUTION OF ITS CETILAR PRODUCTS LINE IN THAILAND WHICH WILL TAKE PLACE BY JUNE 2019

BRIEF-Pharmanutra Signs Partnership Agreement With Fresenius Kabi Switzerland

* SAYS SIGNED PARTNERSHIP AGREEMENT WITH FRESENIUS KABI SWITZERLAND Source text for Eikon:

BRIEF-Pharmanutra 2017 Consolidated Revenue Of EUR 37.8 Million, Up 14.5% YoY

* SAYS FY 2017 CONSOLIDATED REVENUE OF EUR 37.8 MILLION, UP 14.5% VERSUS YEAR AGO

BRIEF-Pharmanutra H1 net profit up at EUR 2.9 mln

* H1 REVENUES FROM SALES AT EUR 18.4 MILLION, UP 14.4 PERCENT YEAR ON YEAR

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up